𝐀𝐒𝐇 𝟐𝟎𝟐𝟓: @olagherej, whose life was changed after he participated in a clinical trial for a CRISPR based gene therapy for sickle cell disease, is attending his first ASH. Here's his message for the industry.

Listen to this…. With curative therapies, it’s not really “one and done!” The cured patient needs support.

Driven by GLP-1s, prescription drug spending explodes at major health insurers. Some insurers spent more on drugs in nine months this year than they did in all of 2024.

Observational data (fashionable term is RWE) is highly susceptible to selection bias. It is completely predictable that an RCT would not reproduce the findings from observational data with GLP1s in AD, particularly when the MoA is so tenuous.

On AlphaFold's 5th anniversary, some remarkable metrics on its utilization & impact 40,000 citations and counting, spanning a broad range of disciplines, generated by more than 3 million users worldwide Truly a before and after moment for science

Interesting context for Galapagos's predicament: "Surely there’s a temptation to...[wind] down the...company? 'Under Belgian rules...it takes a 75% vote.... Gilead owns 25% and doesn't have any interest in doing that.'" https://t.co/f1EKHky2GR

Retro Bio is a headscatcher. The lead program is an autophagy enhancer in GLP studies? Earlier programs are iPSCs for Alzheimer's? Raising $1B at a $5B valuation? Holy cow crazy. The probability that this works out for investors is near zero.

@PirateWaffle @richtrades100 I think the market can reasonably expect companies to not withhold data that they are clearly sitting on. I really dislike it when mgmt teams are effectively trying to tell me how I should think. Show me all the relevant data and let me come to my own conclusions.

https://t.co/EFxtXDl9Ua

This is an incredible/remarkable advance in rapid testing for 14 pathogens, in a single test, from a single swab. Now, you can answer the question, "What do I have" w/ greater clarity...at same cost as single target test. A game changer. H/t @Measie_ @BrusJulian for charging

Australia just recorded zero cervical cancer cases in women under 25 - for the first time since records began in 1982. This is what happens when a country commits to HPV vaccination and screening. We protect our girls and save lives.

It's happening https://t.co/UBie4ChQXH

R.I.P. Molly!

The reductionist days of "good" and "bad" cholesterol are over. We've learned so much more about Lp(a), APOB, HDL and more https://t.co/23qygaFfvA as I reviewed in Super Agers https://t.co/7XbpL7F7e1

Antibodies are simply not the right modality for tau, which primarily causes its pathology within the cell.

Big news and a pleasant surprise after recent milvexian failure in CAD/ACS. Gives reason for optimism for milvexian in stroke and other ongoing clinical trials.

Thirdhand smoke? Pretty absurd from a public health standpoint and just another barrier to affordable housing in CA (which is a real public health concern). https://t.co/Mid962bJ0b

I’ve had the pleasure to work with Arrowhead to get expanded access to Plozasiran. It’s been life changing for my patient, like a miracle drug. Maybe the most humbling experience I’ve had in medicine to see a drug quickly cure a previously intractable disease. Congratulations!

And there are 2 key biological differences with QURE’s approach: 1) addresses exon 1 fragments (tominersen and WVE do not) 2) biodistribution to striatum, whereas tominersen (and WVE) do not get adequate exposure in deep brain